Pediatric HLH Treatment Outcomes with Ruxolitinib Versus HLH-94

67 pediatric patients with hemophagocytic lymphohistiocytosis were analyzed in a single-center retrospective study. The data compares 12-month overall survival, early complete response rates, and cumulative chemotherapy exposure between a ruxolitinib-based regimen (n=27) and the conventional HLH-94 protocol (n=40).

Use Cases

• Compare 12-month overall survival (OS) rates between the ruxolitinib-based and HLH-94 treatment groups
• Analyze early complete response (CR) rates at weeks 2, 4, and 8 across patient cohorts
• Model the relationship between key inflammatory markers like ferritin, IFN-γ, and IL-10 and treatment response
• Assess the distribution of cumulative glucocorticoid and etoposide exposure doses between the two regimens

Strengths

• Data covers 67 pediatric patient records from a clinical study
• Includes comparison of multiple clinical endpoints: 12-month OS, early CR rates, and chemotherapy exposure
• Study design provides a clear historical control group (HLH-94) versus a treatment group (ruxolitinib-based)

Limitations

• Small sample size of 67 total patients limits statistical power for subgroup analyses
• Single-center retrospective design may introduce selection bias and limit generalizability
• Temporal coverage is limited to patients treated from 2022 to 2024

Provenance

Source

figshare, authored by Na Song

Collection Method

Single-center, retrospective historical control study

Time Range

Patients treated from 2022 to 2024

Freshness

Last updated in March 2026.

Geography

null